Quality measures are used to track patient care, connect outcomes with processes, and meet third-party payer requirements, such as the Merit-based Incentive Payment System (MIPS). Reg-ent allows participants to track performance and benchmark against peers in Reg-ent for specialty-specific (i.e., QCDR) and public (i.e., QPP) measures.
QCDR Measures
Reg-ent’s 2020 Qualified Clinical Data Registry (QCDR) designation includes approval of 17 otolaryngology-specific measures developed by and for AAO-HNS members. Reg-ent participants who have direct EHR integration with Reg-ent may use the QCDR measures for MIPS 2020 reporting. Reg-ent Web Tool participants do not have access to the QCDR measures but are able to use QPP measures for MIPS. See below for the list of QCDR measures in Reg-ent and their measure specifications.
Age-related Hearing Loss
- AAO16 – Age-related Hearing Loss: Audiometric Evaluation+
- AAO17 – Age-related Hearing Loss: Advanced Diagnostic Imaging of Bilateral Presbycusis or Symmetric SNHL+
Allergic Rhinitis
- AAO23 – Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines
- AAO24 – Allergic Rhinitis: Avoidance of Leukotriene Inhibitors+
Bell’s Palsy
Dysphonia
Otitis Media with Effusion (OME)
- AAO21 – Otitis Media with Effusion: Hearing Test for Chronic OME > 3 months
- AAO31 – Otitis Media with Effusion (OME): Avoidance of Inappropriate Use of Medications+
Tympanostomy Tubes
- AAO12 – Tympanostomy Tubes: Topical Ear Drop Monotherapy Acute Otorrhea+
- AAO20 – Tympanostomy Tubes: Hearing Test
- AAO36 – Tympanostomy Tubes: Resolution of Otitis Media with Effusion in Adults and Children*
Neurotology
- AAO29 – Quality of Life for Patients with Neurotology Disorders*
- AAO32 – Standard BPPV Management+
- AAO35 – Benign Positional Paroxysmal Vertigo (BPPV): Dix-Hallpike and Canalith Repositioning
Rhinoplasty
- ASPS16 – Airway Assessment for Patients Undergoing Rhinoplasty+
- ASPS17 – Patient Satisfaction with Rhinoplasty Procedure*
- ASPS18 – Shared-decision Making for Post-operative Management of Discomfort Following Rhinoplasty+
QPP Measures
In addition to the QCDR measures, Reg-ent offers Quality Payment Program (QPP) measures. These measures are publicly available through CMS and cover topics both general and otolaryngology-specific. All Reg-ent participants have access to QPP measures for MIPS 2020 reporting. See below for the list of QPP measures in Reg-ent and their measure specifications:
Acute Otitis Externa
Adult Sinusitis
- QPP 331 – Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)+
- QPP 332 – Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)+
- QPP 333 – Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)+
Asthma
- QPP 398 – Optimal Asthma Control*
- QPP 444 – Medication Management for People with Asthma+
Falls
- QPP 154 – Falls: Risk Assessment+
- QPP 155 – Falls: Plan of Care+
Medication
- QPP 130 – Documentation of Current Medications in the Medical Record+^
- QPP 238 – Use of High-Risk Medications in the Elderly+^
Opioid Therapy
- QPP 408 – Opioid Therapy Follow-up Evaluation+
- QPP 412 – Documentation of Signed Opioid Treatment Agreement+
- QPP 414 – Evaluation or Interview for Risk of Opioid Misuse+
- QPP 468 – Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)+
Otitis Media with Effusion
Perioperative Care
- QPP 021 – Perioperative Care: Selection of Prophylactic Antibiotic — First OR Second Generation Cephalosporin+
- QPP 023 – Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)+
Preventive Care & Screening
- QPP 110 – Preventive Care and Screening: Influenza Immunization^
- QPP 111 – Pneumococcal Vaccination Status for Older Adults^
- QPP 128 – Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan^
- QPP 226 – Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention^
- QPP 317 – Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented^
- QPP 402 – Tobacco Use and Help with Quitting Among Adolescents
- QPP 431 – Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling
Respiratory Diseases
- QPP 065 – Appropriate Treatment for Children with Upper Respiratory Infection (URI)+^
- QPP 066 – Appropriate Testing for Children with Pharyngitis+^
- QPP 116 – Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis+
Sleep Apnea
- QPP 277 – Sleep Apnea: Severity Assessment at Initial Diagnosis
- QPP 279 – Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy
Surgery
- QPP 355 – Unplanned Reoperation within the 30 Day Postoperative Period*
- QPP 356 – Unplanned Hospital Readmission within 30 Days of Principal Procedure*
- QPP 357 – Surgical Site Infection (SSI)*
- QPP 358 – Patient-Centered Surgical Risk Assessment and Communication+
Other
- QPP 047 – Advance Care Plan+
- QPP 261 – Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness+
- QPP 265 – Biopsy Follow-Up+
- QPP 374 – Closing the Referral Loop: Receipt of Specialist Report+^
- QPP 404 – Anesthesiology Smoking Abstinence*
- QPP 406 – Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients+
- QPP 435 – Quality of Life Assessment For Patients With Primary Headache Disorders*
- QPP 440 – Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time – Pathologist to Clinician+
*Denotes Outcome Measure
+Denotes High Priority Measure
^Denotes eCQM
